• Something wrong with this record ?

A Clinical-Stage Cysteine Protease Inhibitor blocks SARS-CoV-2 Infection of Human and Monkey Cells

DM. Mellott, CT. Tseng, A. Drelich, P. Fajtová, BC. Chenna, DH. Kostomiris, J. Hsu, J. Zhu, ZW. Taylor, KI. Kocurek, V. Tat, A. Katzfuss, L. Li, MA. Giardini, D. Skinner, K. Hirata, MC. Yoon, S. Beck, AF. Carlin, AE. Clark, L. Beretta, D....

. 2021 ; 16 (4) : 642-650. [pub] 20210331

Language English Country United States

Document type Journal Article, Research Support, N.I.H., Extramural

Persistent link   https://www.medvik.cz/link/bmc21018820

Grant support
N01AI30048 NIAID NIH HHS - United States
R24 AI120942 NIAID NIH HHS - United States

Host-cell cysteine proteases play an essential role in the processing of the viral spike protein of SARS coronaviruses. K777, an irreversible, covalent inactivator of cysteine proteases that has recently completed phase 1 clinical trials, reduced SARS-CoV-2 viral infectivity in several host cells: Vero E6 (EC50< 74 nM), HeLa/ACE2 (4 nM), Caco-2 (EC90 = 4.3 μM), and A549/ACE2 (<80 nM). Infectivity of Calu-3 cells depended on the cell line assayed. If Calu-3/2B4 was used, EC50 was 7 nM, but in the ATCC Calu-3 cell line without ACE2 enrichment, EC50 was >10 μM. There was no toxicity to any of the host cell lines at 10-100 μM K777 concentration. Kinetic analysis confirmed that K777 was a potent inhibitor of human cathepsin L, whereas no inhibition of the SARS-CoV-2 cysteine proteases (papain-like and 3CL-like protease) was observed. Treatment of Vero E6 cells with a propargyl derivative of K777 as an activity-based probe identified human cathepsin B and cathepsin L as the intracellular targets of this molecule in both infected and uninfected Vero E6 cells. However, cleavage of the SARS-CoV-2 spike protein was only carried out by cathepsin L. This cleavage was blocked by K777 and occurred in the S1 domain of the SARS-CoV-2 spike protein, a different site from that previously observed for the SARS-CoV-1 spike protein. These data support the hypothesis that the antiviral activity of K777 is mediated through inhibition of the activity of host cathepsin L and subsequent loss of cathepsin L-mediated viral spike protein processing.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21018820
003      
CZ-PrNML
005      
20210830100403.0
007      
ta
008      
210728s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acschembio.0c00875 $2 doi
035    __
$a (PubMed)33787221
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Mellott, Drake M
245    12
$a A Clinical-Stage Cysteine Protease Inhibitor blocks SARS-CoV-2 Infection of Human and Monkey Cells / $c DM. Mellott, CT. Tseng, A. Drelich, P. Fajtová, BC. Chenna, DH. Kostomiris, J. Hsu, J. Zhu, ZW. Taylor, KI. Kocurek, V. Tat, A. Katzfuss, L. Li, MA. Giardini, D. Skinner, K. Hirata, MC. Yoon, S. Beck, AF. Carlin, AE. Clark, L. Beretta, D. Maneval, V. Hook, F. Frueh, BL. Hurst, H. Wang, FM. Raushel, AJ. O'Donoghue, JL. de Siqueira-Neto, TD. Meek, JH. McKerrow
520    9_
$a Host-cell cysteine proteases play an essential role in the processing of the viral spike protein of SARS coronaviruses. K777, an irreversible, covalent inactivator of cysteine proteases that has recently completed phase 1 clinical trials, reduced SARS-CoV-2 viral infectivity in several host cells: Vero E6 (EC50< 74 nM), HeLa/ACE2 (4 nM), Caco-2 (EC90 = 4.3 μM), and A549/ACE2 (<80 nM). Infectivity of Calu-3 cells depended on the cell line assayed. If Calu-3/2B4 was used, EC50 was 7 nM, but in the ATCC Calu-3 cell line without ACE2 enrichment, EC50 was >10 μM. There was no toxicity to any of the host cell lines at 10-100 μM K777 concentration. Kinetic analysis confirmed that K777 was a potent inhibitor of human cathepsin L, whereas no inhibition of the SARS-CoV-2 cysteine proteases (papain-like and 3CL-like protease) was observed. Treatment of Vero E6 cells with a propargyl derivative of K777 as an activity-based probe identified human cathepsin B and cathepsin L as the intracellular targets of this molecule in both infected and uninfected Vero E6 cells. However, cleavage of the SARS-CoV-2 spike protein was only carried out by cathepsin L. This cleavage was blocked by K777 and occurred in the S1 domain of the SARS-CoV-2 spike protein, a different site from that previously observed for the SARS-CoV-1 spike protein. These data support the hypothesis that the antiviral activity of K777 is mediated through inhibition of the activity of host cathepsin L and subsequent loss of cathepsin L-mediated viral spike protein processing.
650    _2
$a zvířata $7 D000818
650    _2
$a antivirové látky $x farmakologie $7 D000998
650    _2
$a kathepsin L $x antagonisté a inhibitory $x metabolismus $7 D056668
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a Cercopithecus aethiops $7 D002522
650    _2
$a inhibitory cysteinových proteinas $x farmakologie $7 D015853
650    _2
$a lidé $7 D006801
650    _2
$a mikrobiální testy citlivosti $7 D008826
650    _2
$a fenylalanin $x farmakologie $7 D010649
650    _2
$a piperaziny $x farmakologie $7 D010879
650    _2
$a proteinové domény $7 D000072417
650    _2
$a proteolýza $7 D059748
650    _2
$a SARS-CoV-2 $x účinky léků $7 D000086402
650    _2
$a glykoprotein S, koronavirus $x chemie $x metabolismus $7 D064370
650    _2
$a tosylové sloučeniny $x farmakologie $7 D014105
650    _2
$a Vero buňky $7 D014709
650    _2
$a internalizace viru $x účinky léků $7 D053586
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
700    1_
$a Tseng, Chien-Te $u Department of Microbiology and Immunology, University of Texas, Medical Branch, 3000 University Boulevard, Galveston, Texas 77755-1001, United States
700    1_
$a Drelich, Aleksandra $u Department of Microbiology and Immunology, University of Texas, Medical Branch, 3000 University Boulevard, Galveston, Texas 77755-1001, United States
700    1_
$a Fajtová, Pavla $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California 92093, United States $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 16610 Prague, Czech Republic
700    1_
$a Chenna, Bala C
700    1_
$a Kostomiris, Demetrios H
700    1_
$a Hsu, Jason $u Department of Microbiology and Immunology, University of Texas, Medical Branch, 3000 University Boulevard, Galveston, Texas 77755-1001, United States
700    1_
$a Zhu, Jiyun
700    1_
$a Taylor, Zane W
700    1_
$a Kocurek, Klaudia I
700    1_
$a Tat, Vivian $u Department of Microbiology and Immunology, University of Texas, Medical Branch, 3000 University Boulevard, Galveston, Texas 77755-1001, United States
700    1_
$a Katzfuss, Ardala
700    1_
$a Li, Linfeng
700    1_
$a Giardini, Miriam A $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California 92093, United States
700    1_
$a Skinner, Danielle $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California 92093, United States
700    1_
$a Hirata, Ken $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California 92093, United States
700    1_
$a Yoon, Michael C $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California 92093, United States
700    1_
$a Beck, Sungjun $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California 92093, United States
700    1_
$a Carlin, Aaron F $u Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, California 92037, United States
700    1_
$a Clark, Alex E $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California 92093, United States
700    1_
$a Beretta, Laura $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California 92093, United States
700    1_
$a Maneval, Daniel
700    1_
$a Hook, Vivian $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California 92093, United States
700    1_
$a Frueh, Felix
700    1_
$a Hurst, Brett L
700    1_
$a Wang, Hong
700    1_
$a Raushel, Frank M
700    1_
$a O'Donoghue, Anthony J $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California 92093, United States
700    1_
$a de Siqueira-Neto, Jair Lage $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California 92093, United States
700    1_
$a Meek, Thomas D
700    1_
$a McKerrow, James H $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California 92093, United States
773    0_
$w MED00179502 $t ACS chemical biology $x 1554-8937 $g Roč. 16, č. 4 (2021), s. 642-650
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33787221 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100403 $b ABA008
999    __
$a ok $b bmc $g 1689799 $s 1139266
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 16 $c 4 $d 642-650 $e 20210331 $i 1554-8937 $m ACS chemical biology $n ACS Chem Biol $x MED00179502
GRA    __
$a N01AI30048 $p NIAID NIH HHS $2 United States
GRA    __
$a R24 AI120942 $p NIAID NIH HHS $2 United States
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options